Results 121 to 130 of about 188,688 (357)

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi   +19 more
wiley   +1 more source

Optimization and comparative study of Bacillus consortia for cellulolytic potential and cellulase enzyme activity

open access: yesOpen Life Sciences
Lignocellulosic biomass, owing to its recalcitrant nature, requires a consortium of enzymes for its breakdown. The present study deals with the isolation of cellulolytic bacterial strains from landfill leachate collected from the Pulau Burung landfill ...
Chukwuma Ogechukwu Bose   +6 more
doaj   +1 more source

Local Delivery Support Guide: support to help you deliver the 14-19 reforms in your area in 2010-11 [PDF]

open access: yes, 2010
"This Guide sets out much of the support available in 2010-11 to help you deliver the 14-19 reforms in your local area. It is primarily aimed at Directors of Children’s Services and 14-19 leads in local authorities and the leaders and managers within ...

core  

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende   +26 more
wiley   +1 more source

VLSI Revisited - Revival in Japan [PDF]

open access: yes
This paper describes the abundance of semiconductor consortia that have come into existence in Japan since the mid-1990s. They clearly reflect the ambition of the government - through its reorganized ministry METI and company initiatives - to regain some
Sigurdson, Jon
core  

University press publishing consortium for Africa : lessons from academic libraries [PDF]

open access: yes, 2005
This paper presents the results of a case study of the policies and practices of six African university presses. Based on the findings, it posits the formation of a consortium of African university presses. It borrows heavily from consortium formation in
Darko-Ampem, Kwasi
core  

Complementarity of Long‐Reads and Optical Mapping in Parkinson's Disease for Structural Variants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Long‐read sequencing and optical genome mapping technologies have the ability to detect large and complex structural variants. This has led to the discovery of novel pathogenic variants in neurodegenerative movement disorders. Thus, we aimed to systematically compare the SV detection capabilities of OGM and ONT in Parkinson's disease.
André Fienemann   +17 more
wiley   +1 more source

Evaluation of Use of Consortium of e-Resources in Agriculture in Context of Kerala Agricultural University [PDF]

open access: yes, 2012
As digital information resources available online are increasing at an exponential rate, several practices have evolved for the economic and effective delivery of such information to the end users.
Francis, A.T.
core   +1 more source

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen   +7 more
wiley   +1 more source

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy